Huahai Pharmaceutical: Subsidiary Obtains Drug Registration Certificate for Fumaric Acid Vorinostat Tablets

Hua Hai Pharmaceutical announced that the company recently received the drug registration certificate for Fumarate Venlafaxine Tablets approved by the National Medical Products Administration, with specifications of 20mg and 10mg, and approval numbers Guoyao Zhunzi H20265598 and Guoyao Zhunzi H20265599. This drug is used for the treatment of reflux esophagitis and has been approved for sale in China since December 2019, with market sales amounting to approximately 282 million yuan in the first quarter of 2026. The company has invested about 4.22 million yuan in research and development, and the approval will enrich the company's product line and enhance its competitiveness. However, production and sales are influenced by policies and market factors, and investors should be aware of the risks.